渤健Biogen （BIIB） 2017年全球影响报告「NASDAQ」.pdf

《渤健Biogen （BIIB） 2017年全球影响报告「NASDAQ」.pdf》由会员分享，可在线阅读，更多相关《渤健Biogen （BIIB） 2017年全球影响报告「NASDAQ」.pdf（73页珍藏版）》请在三个皮匠报告上搜索。

1、2017 Global Impact ReportTable of ContentsOur Purpose,Our Impact3A Note from our CEO7Our Business10Our Commitments15Our Community29Our Environment41GRI Report49This report contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act

2、of 1995,including statements relating to Biogens business activities;Biogens strategy and plans;potential of Biogens commercial business and pipeline programs;capital allocation and investment strategy;clinical trials and data readouts and presentations;regulatory filings and the timing thereof;and

3、anticipated benefits and potential of investments,collaborations and business development activities.These forward-looking statements may be accompanied by words such as“aim,”“anticipate,”“believe,”“could,”“estimate,”“except,”“forecast,”“goal,”“intend,”“may,”“plan,”“potential,”“possible,”“will”and o

4、ther words and terms of similar meaning.Drug development and commercialization involve a high degree of risk,and only a small number of research and development programs result in commercialization of a product.Results in early stage clinical trials may not be indicative of full results or results f

5、rom later stage or larger scale clinical trials and do not ensure regulatory approval.You should not place undue reliance on these statements or the scientific data presented.These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in

6、 such statements,including risks relating to difficulties in obtaining and maintaining adequate coverage,pricing and reimbursement for Biogens products;the occurrence of adverse safety events,restrictions on use with Biogens products or product liability claims;uncertainty of success in developing,l